Collectively, these findings illustrated KDM3A as a tumour promoter in lung cancer through FXYD3 suppression by elevating DCLK1 via the removal of the methylation of H3K9me2 in the DCLK1 promoter region. Here, KDM3A is linked to lung carcinoma.